ARTICLE | Clinical News

Halofuginone small molecule collagen type I synthesis inhibitor regulatory update

April 10, 2000 7:00 AM UTC

Collgard received U.S. Patent No. 6,028,075 covering the use of Halofuginone and derivatives to treat bladder, prostate, breast, skin and lung tumors. The company expects to begin clinical testing of ...